The role of the combination of bone and fall related risk factors on short-term subsequent fracture risk and mortality

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Huntjens, Kirsten M B ^a   Van Geel, Tineke A C M ^b   Van Helden, Svenhjalmar ^c   Van Den Bergh, Joop ^a,c,d   Willems, Paul ^a   Winkens, Bjorn ^b   Geusens, Piet P ^a,d   Brink, Peter R G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Isala Klinieken ^*  (Netherlands)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

ADULT; ARTICLE; FALLING; FEMALE; FRACTURE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; RISK FACTOR;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84875689092     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-121     Document Type: Article

References (29)

1. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M, J Bone Miner Res 2000 15 4 721 739 10780864
2. Fracture risk following an osteoporotic fracture. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B, Osteoporos Int 2004 15 3 175 179 10.1007/s00198-003-1514-0 14691617
3. Risk of subsequent fracture after low-trauma fracture in men and women. Center JR, Bliuc D, Nguyen TV, Eisman JA, JAMA 2007 297 4 387 394 10.1001/jama.297.4.387 17244835
4. Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, Winkens B, Brink P, van Helden S, Osteoporos Int 2010 21 12 2075 2082 10.1007/s00198-010-1178-5 20162259
5. Risk of new clinical fractures within 2 years following a fracture. van Helden S, Cals J, Kessels F, Brink P, Dinant GJ, Geusens P, Osteoporos Int 2006 17 3 348 354 10.1007/s00198-005-2026-x 16378167
6. Clinical subsequent fractures cluster in time after first fractures. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ, Ann Rheum Dis 2008 68 1 99 102 10.1136/ard.2008.092775 18677009
7. Bone and fall-related fracture risks in women and men with a recent clinical fracture. van Helden S, van Geel AC, Geusens PP, Kessels A, Nieuwenhuijzen Kruseman AC, Brink PR, J Bone Joint Surg Am 2008 90 2 241 248 10.2106/JBJS.G.00150 18245581
8. FRAX, WHO Fracture Risk Assessment Tool http://www.shef.ac.uk/FRAX/?lang= en
9. Garvan Institute, Fracture Risk Calculator http://garvan.org.au/ promotions/bone-fracture-risk/calculator/
10. Mortality after osteoporotic fractures. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B, Osteoporos Int 2004 15 1 38 42 10.1007/s00198-003-1490-4 14593451
11. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR, JAMA 2009 301 5 513 521 10.1001/jama.2009.50 19190316
12. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate. Harris ST, Osteoporos Int 2001 12 Suppl 3 11 S16 11846336
13. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Boonen S, Laan RF, Barton IP, Watts NB, Osteoporos Int 2005 16 10 1291 1298 10.1007/s00198-005- 1945-x 15986101
14. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, N Engl J Med 2009 361 8 756 765 10.1056/NEJMoa0809493 19671655
15. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, N Engl J Med 2007 356 18 1809 1822 10.1056/NEJMoa067312 17476007
16. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, J Clin Endocrinol Metab 2000 85 11 4118 4124 10.1210/jc.85.11.4118 11095442
17. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Osteoporos Int 2000 11 1 83 91 10.1007/s001980050010 10663363
18. The role of falls in fracture prediction. Bischoff-Ferrari HA, Curr Osteoporos Rep 2011 9 3 116 121 10.1007/s11914-011-0059-y 21655932
19. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E, J Bone Miner Res 2012 27 10 2039 2046 10.1002/jbmr.1698 22836222
20. KvdG CBO, Osteoporose, tweede herziene richtlijn Communications: Van Zuiden 2002
21. Preventie van valincidenten bij ouderen http://www.diliguide.nl/document/ 1015/osteoporose-en-fractuurpreventie.html
22. Risk of new vertebral fracture in the year following a fracture. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, JAMA 2001 285 3 320 323 10.1001/jama.285.3.320 11176842
23. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P, J Bone Miner Res 2009 24 7 1299 1307 10.1359/jbmr.090207 19257816
24. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA, Lancet 1999 353 9156 878 882 10.1016/S0140-6736(98)09075-8 10093980
25. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, Maturitas 2009 62 2 105 108 10.1016/j.maturitas.2008.11.022 19135323
26. Impact of guideline implementation by a fracture nurse on subsequent fractures and mortality in patients presenting with non-vertebral fractures. Huntjens KM, van Geel TC, Geusens PP, Winkens B, Willems P, van den Bergh J, Brink PR, van Helden S, Injury 2011 42 Suppl 4 39 S43 21939802
27. Osteoporosis medication and reduced mortality risk in elderly women and men. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, J Clin Endocrinol Metab 2011 96 4 1006 1014 10.1210/jc.2010-2730 21289270
28. Implementation of osteoporosis guidelines: a survey of five large fracture liaison services in the Netherlands. Huntjens KM, van Geel TA, Blonk MC, Hegeman JH, van der Elst M, Willems P, Geusens PP, Winkens B, Brink P, van Helden SH, Osteoporos Int 2011 22 7 2129 2135 10.1007/s00198-010-1442-8 21052640
29. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Bone 2011 49 3 493 498 10.1016/j.bone.2011.05.007 21605715